Authorization tracking and renewal management are separate workflows from PA submission, and most practices understaff both
They work closely with patients to develop treatment approaches that align with personal preferences and long-term health goals
According to NICE Technology Appraisal 875 (TA875) , Wegovy (semaglutide) is available on the NHS only through specialist weight management services and for adults who meet specific criteria, including: Generally, a body mass index (BMI) of 35 kg/m or greater with weight-related comorbidities (with lower thresholds for certain ethnic groups) Referral to and engagement with a specialist weight management service (Tier 3) Treatment limited to a maximum of 2 years This differs from the broader marketing authorisation criteria in the SmPC, which includes adults with a BMI of 30 kg/m or greater, or 27 kg/m or greater with weight-related comorbidities
Practical strategies to support success There are practical strategies that you can try to help support meaningful weight loss results when taking a GLP-1 drug
However, some patients taking Wegovy experience gastrointestinal side effects such as nausea, vomiting, or indigestion, particularly when starting treatment or increasing the dose
Informacin adicional Productos relacionados DESCARGA GRATIS Nuevo en este mundo del BioHacking
